KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA: KARS)

Ultime notizie per KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA:KARS)

Consumer Cyclical

Basic Materials

Other

Industrials

Technology

Consumer Defensive

Real Estate

Energy

The fund will invest at least 80% of its total assets in components of the index, depositary receipts, including ADRs, representing such components, and securities underlying depositary receipts in the index. The index is designed to track the equity market performance of companies engaged in the production of electric vehicles or their components or in other initiatives that may change the future of mobility, as determined by index provider. The fund is non-diversified.

Tesla, Inc.

Byd Co Ltd

Li Auto Inc-Class A

Panasonic Corp

Rivian Automotive

Samsung Sdi Co Ltd

Albemarle Corp.

KraneShares Electric Vehicles and Future Mobility Index ETF

KARSAN OTOMOTIV SNAYII by KARSAN OTOMOTIV SANAYII VE TICARET AS

Karsan Otomotiv Sanayii Ve Ticaret AS

<p>WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that WR Berkley will report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>The market awaits WR Berkley's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.12, leading to a 0.75% increase in the share price the following trading session.</p>
<p>Here's a look at WR Berkley's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.92</td>
<td>0.96</td>
<td>0.92</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.04</td>
<td>0.97</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275616_0.png" alt="eps graph" /></p>
<h3>Market Performance of WR Berkley's Stock</h3>
<p>Shares of WR Berkley were trading at $61.04 as of October 17. Over the last 52-week period, shares are up 46.33%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WRB/earnings"><strong>To track all earnings releases for WR Berkley visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Exploring WR Berkley's Earnings Expectations

<p>Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Alexandria Real Estate to report an <strong>earnings per share</strong> (EPS) of $2.37.</p>
<p>Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 3.52% drop in the share price on the following day.</p>
<p>Here's a look at Alexandria Real Estate's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>2.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>2.35</td>
<td>2.28</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Alexandria Real Estate were trading at $121.25 as of October 17. Over the last 52-week period, shares are up 29.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Alexandria Real Estate</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.</p>
<p>A total of 8 analyst ratings have been received for Alexandria Real Estate, with the consensus rating being Neutral. The average one-year price target stands at $128.88, suggesting a potential 6.29% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ventas, Healthpeak Properties and Omega Healthcare Invts, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Ventas, with an average 1-year price target of $65.88, suggesting a potential 45.67% downside.</li>
<li>As per analysts' assessments, Healthpeak Properties is favoring an Outperform trajectory, with an average 1-year price target of $24.29, suggesting a potential 79.97% downside.</li>
<li>Omega Healthcare Invts received a Neutral consensus from analysts, with an average 1-year price target of $42.2, implying a potential 65.2% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Ventas, Healthpeak Properties and Omega Healthcare Invts, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>7.40%</td>
<td>$549.48M</td>
<td>0.23%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Outperform</td>
<td>8.55%</td>
<td>$519.18M</td>
<td>0.20%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>27.31%</td>
<td>$413.85M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>1.02%</td>
<td>$249.00M</td>
<td>3.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alexandria Real Estate ranks in the middle for revenue growth among its peers. It is at the bottom for gross profit and return on equity.</p>
<h3>About Alexandria Real Estate</h3>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Financial Insights: Alexandria Real Estate</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Alexandria Real Estate showcased positive performance, achieving a revenue growth rate of <strong>7.4%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Alexandria Real Estate's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.6%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Alexandria Real Estate's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.23%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.11%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Alexandria Real Estate's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.7</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ARE/earnings"><strong>To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Alexandria Real Estate's Earnings

<p>Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Guaranty Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.60.</p>
<p>The market awaits Guaranty Bancshares's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 4.17% increase in the share price on the following day.</p>
<p>Here's a look at Guaranty Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.47</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275597_0.png" alt="eps graph" /></p>
<h3>Performance of Guaranty Bancshares Shares</h3>
<p>Shares of Guaranty Bancshares were trading at $35.58 as of October 17. Over the last 52-week period, shares are up 29.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GNTY/earnings"><strong>To track all earnings releases for Guaranty Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GNTY

An Overview of Guaranty Bancshares's Earnings

<p>KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect KKR Real Estate Finance to report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>The announcement from KKR Real Estate Finance is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 14.57% increase in the share price the following trading session.</p>
<p>Here's a look at KKR Real Estate Finance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.66</td>
<td>0.34</td>
<td>0.11</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.57</td>
<td>0.39</td>
<td>-0.37</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>-2.0%</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275590_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of KKR Real Estate Finance were trading at $12.0 as of October 17. Over the last 52-week period, shares are up 19.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KREF/earnings"><strong>To track all earnings releases for KKR Real Estate Finance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KREF

Examining the Future: KKR Real Estate Finance's Earnings Outlook

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Cathay General will report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>Cathay General bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 0.65% increase in the share price the next day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275580_0.png" alt="eps graph" /></p>
<h3>Performance of Cathay General Shares</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.7%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CATY

Cathay General's Earnings Outlook

<p><a href="https://sam.gov/opp/a23cafbe66df409fa4f7048036538d1e/view" title="https://sam.gov/opp/a23cafbe66df409fa4f7048036538d1e/view">https://sam.gov/opp/a23cafbe66df409fa4f7048036538d1e/view</a></p>


News

Contracts

LUMN

The 502d Contracting Squadron, 395 B Street West Suite 2, Joint Base San Antonio-TX 78150, Intends To Solicit And Award A Sole Source Firm-Fixed-Price Contract To Lumen Technologies; No Financial Terms Disclosed

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Nucor will report an <strong>earnings per share</strong> (EPS) of $1.49.</p>
<p>The market awaits Nucor's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.33 in the last quarter, leading to a 1.1% drop in the share price on the following day.</p>
<p>Here's a look at Nucor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.35</td>
<td>3.65</td>
<td>2.87</td>
<td>4.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.68</td>
<td>3.46</td>
<td>3.16</td>
<td>4.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275536_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Nucor were trading at $158.09 as of October 17. Over the last 52-week period, shares are up 12.8%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Nucor</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nucor.</p>
<p>The consensus rating for Nucor is Outperform, based on 5 analyst ratings. With an average one-year price target of $170.0, there's a potential 7.53% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and United States Steel, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus among analysts is an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $136.82, indicating a potential 13.45% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Reliance, with an average 1-year price target of $325.0, suggesting a potential 105.58% upside.</li>
<li>Analysts currently favor an Buy trajectory for United States Steel, with an average 1-year price target of $42.64, suggesting a potential 73.03% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Steel Dynamics, Reliance and United States Steel, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-15.18%</td>
<td>$1.19B</td>
<td>3.10%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>-6.28%</td>
<td>$774.84M</td>
<td>3.49%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>-6.11%</td>
<td>$1.09B</td>
<td>3.44%</td>
</tr>
<tr>
<td>United States Steel</td>
<td>Buy</td>
<td>-17.77%</td>
<td>$489M</td>
<td>1.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nucor ranks at the top for Gross Profit and Return on Equity among its peers. However, it ranks at the bottom for Revenue Growth.</p>
<h3>About Nucor</h3>
<p>Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.</p>
<h3>Nucor's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Nucor's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-15.18%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Nucor's net margin excels beyond industry benchmarks, reaching <strong>7.95%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.1%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.89%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.33</strong>.</p>
<p><a href="https://www.benzinga.com/quote/NUE/earnings"><strong>To track all earnings releases for Nucor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Nucor's Earnings: A Preview

<p>Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Hexcel to report an <strong>earnings per share</strong> (EPS) of $0.47.</p>
<p>Anticipation surrounds Hexcel's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.04, leading to a 0.26% increase in the share price the following trading session.</p>
<p>Here's a look at Hexcel's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275527_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Hexcel were trading at $62.25 as of October 17. Over the last 52-week period, shares are down 2.8%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Observations about Hexcel</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Hexcel.</p>
<p>With 6 analyst ratings, Hexcel has a consensus rating of Neutral. The average one-year price target is $67.0, indicating a potential 7.63% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Rocket Lab USA and AeroVironment, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>For Rocket Lab USA, analysts project an Outperform trajectory, with an average 1-year price target of $7.12, indicating a potential 88.56% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for AeroVironment, with an average 1-year price target of $224.0, indicating a potential 259.84% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Rocket Lab USA and AeroVironment, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexcel</td>
<td>Neutral</td>
<td>10.15%</td>
<td>$126.60M</td>
<td>3.12%</td>
</tr>
<tr>
<td>Rocket Lab USA</td>
<td>Outperform</td>
<td>71.25%</td>
<td>$27.16M</td>
<td>-8.91%</td>
</tr>
<tr>
<td>AeroVironment</td>
<td>Outperform</td>
<td>24.38%</td>
<td>$81.47M</td>
<td>2.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hexcel is positioned in the middle among its peers for revenue growth. It ranks at the bottom for gross profit. In terms of return on equity, Hexcel is placed in the middle compared to its peers.</p>
<h3>Get to Know Hexcel Better</h3>
<p>Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in commercial aerospace, defense, and other industrial markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and its respective subcontractors.</p>
<h3>A Deep Dive into Hexcel's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Hexcel showcased positive performance, achieving a revenue growth rate of <strong>10.15%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Hexcel's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>9.99%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.12%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Hexcel's ROA excels beyond industry benchmarks, reaching <strong>1.77%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.51</strong>, Hexcel adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/HXL/earnings"><strong>To track all earnings releases for Hexcel visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Hexcel's Earnings Forecast

<p>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Medpace Hldgs to report an <strong>earnings per share</strong> (EPS) of $2.80.</p>
<p>Investors in Medpace Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.21, which was followed by a 18.27% drop in the share price the next day.</p>
<p>Here's a look at Medpace Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.46</td>
<td>2.22</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>3.20</td>
<td>2.46</td>
<td>2.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275512_0.png" alt="eps graph" /></p>
<h3>Performance of Medpace Hldgs Shares</h3>
<p>Shares of Medpace Hldgs were trading at $342.89 as of October 17. Over the last 52-week period, shares are up 55.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Medpace Hldgs</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Medpace Hldgs.</p>
<p>Analysts have provided Medpace Hldgs with 10 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $395.6, suggesting a potential 15.37% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Bio-Techne, Charles River and Bio-Rad Laboratories, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Bio-Techne, with an average 1-year price target of $82.33, indicating a potential 75.99% downside.</li>
<li>Charles River is maintaining an Neutral status according to analysts, with an average 1-year price target of $203.75, indicating a potential 40.58% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Bio-Rad Laboratories, with an average 1-year price target of $378.4, indicating a potential 10.36% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for Bio-Techne, Charles River and Bio-Rad Laboratories are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>14.59%</td>
<td>$153.84M</td>
<td>12.31%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Medpace Hldgs ranks in the middle among its peers for revenue growth, with positive growth compared to some peers. It is at the top for gross profit, indicating strong profitability. However, its return on equity is lower than some peers, placing it in the middle. Overall, Medpace Hldgs shows a balanced performance compared to its peers in these key metrics.</p>
<h3>Get to Know Medpace Hldgs Better</h3>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>A Deep Dive into Medpace Hldgs's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Medpace Hldgs showcased positive performance, achieving a revenue growth rate of <strong>14.59%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.73%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Medpace Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>12.31%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.76%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/earnings"><strong>To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MEDP

Earnings Preview For Medpace Hldgs

<p>Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Enterprise Finl Servs to report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>Enterprise Finl Servs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.15, which was followed by a 12.37% increase in the share price the next day.</p>
<p>Here's a look at Enterprise Finl Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.06</td>
<td>1.11</td>
<td>1.19</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.21</td>
<td>1.07</td>
<td>1.21</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275497_0.png" alt="eps graph" /></p>
<h3>Enterprise Finl Servs Share Price Analysis</h3>
<p>Shares of Enterprise Finl Servs were trading at $53.85 as of October 17. Over the last 52-week period, shares are up 48.98%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EFSC/earnings"><strong>To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EFSC

A Look at Enterprise Finl Servs's Upcoming Earnings Report

<p>WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that WR Berkley will report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>Anticipation surrounds WR Berkley's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.12, leading to a 0.75% increase in the share price the following trading session.</p>
<p>Here's a look at WR Berkley's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.92</td>
<td>0.96</td>
<td>0.92</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.04</td>
<td>0.97</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275484_0.png" alt="eps graph" /></p>
<h3>Performance of WR Berkley Shares</h3>
<p>Shares of WR Berkley were trading at $61.04 as of October 17. Over the last 52-week period, shares are up 46.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WRB/earnings"><strong>To track all earnings releases for WR Berkley visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into WR Berkley's Upcoming Earnings

<p>Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Alexandria Real Estate will report an <strong>earnings per share</strong> (EPS) of $2.37.</p>
<p>Alexandria Real Estate bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 3.52% drop in the share price on the subsequent day.</p>
<p>Here's a look at Alexandria Real Estate's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>2.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>2.35</td>
<td>2.28</td>
<td>2.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Alexandria Real Estate were trading at $121.25 as of October 17. Over the last 52-week period, shares are up 28.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Alexandria Real Estate</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alexandria Real Estate.</p>
<p>The consensus rating for Alexandria Real Estate is Neutral, derived from 8 analyst ratings. An average one-year price target of $128.88 implies a potential 6.29% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Ventas, Healthpeak Properties and Omega Healthcare Invts, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Ventas, with an average 1-year price target of $65.88, suggesting a potential 45.67% downside.</li>
<li>Healthpeak Properties is maintaining an Outperform status according to analysts, with an average 1-year price target of $24.29, indicating a potential 79.97% downside.</li>
<li>Omega Healthcare Invts received a Neutral consensus from analysts, with an average 1-year price target of $42.2, implying a potential 65.2% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Ventas, Healthpeak Properties and Omega Healthcare Invts, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>7.40%</td>
<td>$549.48M</td>
<td>0.23%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Outperform</td>
<td>8.55%</td>
<td>$519.18M</td>
<td>0.20%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>27.31%</td>
<td>$413.85M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Omega Healthcare Invts</td>
<td>Neutral</td>
<td>1.02%</td>
<td>$249.00M</td>
<td>3.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Alexandria Real Estate ranks in the middle for consensus rating. It is at the bottom for revenue growth and gross profit, but at the top for return on equity among its peers.</p>
<h3>Delving into Alexandria Real Estate's Background</h3>
<p>Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.</p>
<h3>Alexandria Real Estate: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Alexandria Real Estate showcased positive performance, achieving a revenue growth rate of <strong>7.4%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Alexandria Real Estate's net margin is impressive, surpassing industry averages. With a net margin of <strong>5.6%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Alexandria Real Estate's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.23%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Alexandria Real Estate's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.11%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.7</strong>, Alexandria Real Estate adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/ARE/earnings"><strong>To track all earnings releases for Alexandria Real Estate visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Exploring Alexandria Real Estate's Earnings Expectations

<p>Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Guaranty Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.60.</p>
<p>The announcement from Guaranty Bancshares is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.11, leading to a 4.17% increase in the share price on the subsequent day.</p>
<p>Here's a look at Guaranty Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.47</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.65</td>
<td>0.58</td>
<td>0.51</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275469_0.png" alt="eps graph" /></p>
<h3>Guaranty Bancshares Share Price Analysis</h3>
<p>Shares of Guaranty Bancshares were trading at $35.58 as of October 17. Over the last 52-week period, shares are up 29.53%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GNTY/earnings"><strong>To track all earnings releases for Guaranty Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Guaranty Bancshares's Earnings Forecast

<p>KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that KKR Real Estate Finance will report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>The market awaits KKR Real Estate Finance's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.09, leading to a 14.57% increase in the share price the following trading session.</p>
<p>Here's a look at KKR Real Estate Finance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.66</td>
<td>0.34</td>
<td>0.11</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.57</td>
<td>0.39</td>
<td>-0.37</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>-2.0%</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275458_0.png" alt="eps graph" /></p>
<h3>Tracking KKR Real Estate Finance's Stock Performance</h3>
<p>Shares of KKR Real Estate Finance were trading at $12.0 as of October 17. Over the last 52-week period, shares are up 19.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KREF/earnings"><strong>To track all earnings releases for KKR Real Estate Finance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KKR Real Estate Finance's Earnings: A Preview

<p><strong>Cathay General</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Cathay General will report an <strong>earnings per share</strong> (EPS) of $0.95. </p>
<p>Cathay General bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 0.65% increase in the share price the next day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275451_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.7%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Cathay General

<p>Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Selective Insurance Gr to report an <strong>earnings per share</strong> (EPS) of $1.65.</p>
<p>Investors in Selective Insurance Gr are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $2.58, leading to a 18.18% drop in the share price on the subsequent day.</p>
<p>Here's a look at Selective Insurance Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.48</td>
<td>1.84</td>
<td>1.94</td>
<td>1.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.10</td>
<td>1.33</td>
<td>1.94</td>
<td>1.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275434_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Selective Insurance Gr were trading at $98.89 as of October 17. Over the last 52-week period, shares are down 3.81%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SIGI/earnings"><strong>To track all earnings releases for Selective Insurance Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SIGI

Earnings Preview For Selective Insurance Gr

<p>Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Hexcel will report an <strong>earnings per share</strong> (EPS) of $0.47.</p>
<p>The announcement from Hexcel is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.04, leading to a 0.26% increase in the share price the following trading session.</p>
<p>Here's a look at Hexcel's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275408_0.png" alt="eps graph" /></p>
<h3>Market Performance of Hexcel's Stock</h3>
<p>Shares of Hexcel were trading at $62.25 as of October 17. Over the last 52-week period, shares are down 2.84%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Opinions on Hexcel</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Hexcel.</p>
<p>The consensus rating for Hexcel is Neutral, derived from 6 analyst ratings. An average one-year price target of $67.0 implies a potential 7.63% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Rocket Lab USA and AeroVironment, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus among analysts is an Outperform trajectory for Rocket Lab USA, with an average 1-year price target of $7.12, indicating a potential 88.56% downside.</li>
<li>For AeroVironment, analysts project an Outperform trajectory, with an average 1-year price target of $224.0, indicating a potential 259.84% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Rocket Lab USA and AeroVironment, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexcel</td>
<td>Neutral</td>
<td>10.15%</td>
<td>$126.60M</td>
<td>3.12%</td>
</tr>
<tr>
<td>Rocket Lab USA</td>
<td>Outperform</td>
<td>71.25%</td>
<td>$27.16M</td>
<td>-8.91%</td>
</tr>
<tr>
<td>AeroVironment</td>
<td>Outperform</td>
<td>24.38%</td>
<td>$81.47M</td>
<td>2.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hexcel ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. Hexcel's return on equity is higher than one peer but lower than another.</p>
<h3>All You Need to Know About Hexcel</h3>
<p>Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in commercial aerospace, defense, and other industrial markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and its respective subcontractors.</p>
<h3>Hexcel's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Hexcel displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.15%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Hexcel's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.99%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hexcel's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.12%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.77%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Hexcel's debt-to-equity ratio is below the industry average. With a ratio of <b>0.51</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/HXL/earnings"><strong>To track all earnings releases for Hexcel visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Hexcel's Future Earnings

<p>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is gearing up to announce its quarterly earnings on Monday, 2024-10-21. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Medpace Hldgs will report an <strong>earnings per share</strong> (EPS) of $2.80.</p>
<p>Anticipation surrounds Medpace Hldgs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.21 in the last quarter, leading to a 18.27% drop in the share price on the following day.</p>
<p>Here's a look at Medpace Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.54</td>
<td>2.46</td>
<td>2.22</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.75</td>
<td>3.20</td>
<td>2.46</td>
<td>2.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275391_0.png" alt="eps graph" /></p>
<h3>Medpace Hldgs Share Price Analysis</h3>
<p>Shares of Medpace Hldgs were trading at $342.89 as of October 17. Over the last 52-week period, shares are up 55.27%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Medpace Hldgs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Medpace Hldgs.</p>
<p>The consensus rating for Medpace Hldgs is Neutral, derived from 10 analyst ratings. An average one-year price target of $395.6 implies a potential 15.37% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Bio-Techne, Charles River and Bio-Rad Laboratories, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Bio-Techne, with an average 1-year price target of $82.33, indicating a potential 75.99% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Charles River, with an average 1-year price target of $203.75, suggesting a potential 40.58% downside.</li>
<li>For Bio-Rad Laboratories, analysts project an Neutral trajectory, with an average 1-year price target of $378.4, indicating a potential 10.36% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Bio-Techne, Charles River and Bio-Rad Laboratories are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>14.59%</td>
<td>$153.84M</td>
<td>12.31%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Medpace Hldgs ranks in the middle among its peers for revenue growth, with positive growth compared to some peers. It is at the top for gross profit, indicating strong profitability. However, its return on equity is lower than some peers, suggesting room for improvement in utilizing shareholder equity effectively. Overall, Medpace Hldgs shows a balanced performance compared to its peers in the analysis.</p>
<h3>Get to Know Medpace Hldgs Better</h3>
<p>Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.</p>
<h3>Unraveling the Financial Story of Medpace Hldgs</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Medpace Hldgs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>14.59%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Medpace Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>16.73%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Medpace Hldgs's ROE excels beyond industry benchmarks, reaching <strong>12.31%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.76%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.17</strong>, Medpace Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/MEDP/earnings"><strong>To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Medpace Hldgs's Earnings Outlook

<p><strong>BOK Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is set to give its latest quarterly earnings report on Monday, 2024-10-21. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BOK Financial will report an <strong>earnings per share</strong> (EPS) of $1.98. </p>
<p>The market awaits BOK Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.32, leading to a 0.74% drop in the share price the following trading session.</p>
<p>Here's a look at BOK Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.34</td>
<td>1.73</td>
<td>1.75</td>
<td>2.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.02</td>
<td>1.91</td>
<td>1.76</td>
<td>2.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275375_0.png" alt="eps graph" /></p>
<h3>Performance of BOK Financial Shares</h3>
<p>Shares of BOK Financial were trading at $114.66 as of October 17. Over the last 52-week period, shares are up 57.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BOKF/earnings"><strong>To track all earnings releases for BOK Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BOKF

BOK Financial's Earnings: A Preview

<p>Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Enterprise Finl Servs to report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>The announcement from Enterprise Finl Servs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.15, leading to a 12.37% increase in the share price on the subsequent day.</p>
<p>Here's a look at Enterprise Finl Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.06</td>
<td>1.11</td>
<td>1.19</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.21</td>
<td>1.07</td>
<td>1.21</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275364_0.png" alt="eps graph" /></p>
<h3>Market Performance of Enterprise Finl Servs's Stock</h3>
<p>Shares of Enterprise Finl Servs were trading at $53.85 as of October 17. Over the last 52-week period, shares are up 48.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EFSC/earnings"><strong>To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Enterprise Finl Servs's Earnings

Is The EV Transition Being Pushed Further Into The Future?

Empire State Manufacturing Survey: Activity Declines Slightly In August

Delays impact 40% of Biden administration's biggest climate projects - FT

Trump would consider ending EV tax credit, naming Elon Musk as adviser - report

The Fed Finally Joins The 'Rate Cut' Party

Portfolio Implications Of Powell's 'Whatever It Takes' Moment

How The U.S. Election Could Impact The Energy Transition

Resilient U.S. Retail Sales Suggests Fed Decision Will Be A Coin Toss

DoE awards $3B for 25 projects to boost U.S. battery production

Winding Road Ahead For China's EV Growth

AAAU

ABAT

ACES

ACTV

AFMC

AFSM

AIRR

ARKK

ARKQ

AVUV

BAPR

BATT

BBRE

BBSC

BGLD

BKSE

BRZU

BYDDF

BYDDY

CALF

CARZ

CBSE

CNRG

CRBN

CTEC

CTEX

DEEP

DFAS

DGRS

DNFGF

DNFGY

DRIV

DUSL

DWAS

EBIZ

ENLAY

EQNR

ERTH

ESML

EVAV

EWZS

FDIS

FDRV

FIBR

FIDU

FLBR

FLQS

FNDA

FPRO

FREL

FRNW

FSTA

FTXR

GBIL

GCLN

GELYF

GELYY

GLDI

GLDM

GLRY

GLTR

GOVT

GOVZ

GRID

GRNTF

GSSC

GWLLF

GWLLY

HAIL

HOMZ

HSMV

HYDR

IAUM

IBUY

ICLN

IDRV

IEDI

IGLD

INDS

ISCB

ISCG

ISCV

ISHP

ISMD

IVOO

IVOV

IVRA

JHSC

JJETF

JPSE

JSML

KAPR

KARS

KBWY

KCCA

KEUA

KJAN

KJUL

KRBN

LGOV

MAGS

MGMT

MORT

NAIL

NBCT

NETL

NURE

NUSC

OILK

OLOXF

OMFS

ONLN

OSCV

OUNZ

OUSM

PHYS

PPTY

PRFZ

PSCC

Comments

KraneShares Electric Vehicles and Future Mobility Index ETF

Notizie

Ultime notizie per KraneShares Electric Vehicles and Future Mobility Index ETF (ARCA:KARS)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO